Presentation of clinical proof-of-concept results at ESPID 2023 Conference

Kriba, (formely Newborn Solutions) is delighted to announce the successful participation of Dr. Sara Ajanovic, MD, MSc, PhD candidate, Paediatrician, and valued member of our team, at the prestigious European Society for Paediatric Infectious Diseases (ESPID) conference in Lisbon this year. Dr. Ajanovic, also a medical research fellow at the Barcelona Institute for Global Health (ISGlobal), presented our groundbreaking proof-of-concept results from the Neosonics device during this renowned event.

At Kriba, we take great pride in sharing our advancements and preliminary results with the remarkable community of professionals present at the ESPID conference. This annual scientific gathering brings together healthcare experts, researchers, and practitioners in the field of pediatric infectious diseases from Europe and around the world.

Sara’s presentation, titled “Meningitis Screening Based on a Novel, Non-Invasive, Transfontanellar Ultrasound Device: A Proof-of-Concept Study”, showcased our revolutionary transfontanellar ultrasound-based and AI powered device, Neosonics. The objective of the study was to validate this technique for meningitis screening, designed to identify white blood cells in cerebrospinal fluid in patients with lumbar puncture criteria.

Conducted in three prominent and high volume Spanish hospitals – University Hospital La Paz and Quirónsalud in Pozuelo de Alarcón (Madrid), and Sant Joan de Déu Children’s Hospital in Barcelona – the results from the study are incredibly promising. With a sensitivity of 100% and specificity of 90%, the device has demonstrated the ability to detect all cases of meningitis and spare 90% of unnecessary lumbar punctures.

Dr. Ajanovic stated, “We are already progressing with great momentum, as we are currently conducting a phase I trial in Spain, Morocco, and Mozambique, with over 170 patients already recruited. The Neosonics device operates similarly to a billirubinometer, providing the number of white blood cells per milliliter on a small screen, revolutionizing meningitis screening.”

During the ESPID conference, Dr. Ajanovic also presented other significant results from ISGlobal projects, including clinical trials in malaria and the Febrile Illness Evaluation in a Broad Range of Endemicities (FIEBRE). FIEBRE, coordinated by the London School of Tropical Medicine and Hygiene (LSHTM), studies fever in sub-Saharan Africa and Southeast Asia to investigate the leading causes of fever in children and adults.

Kriba’s presentation took place during a session focused on prognosis markers and new technologies, which attracted a full room of approximately 350 distinguished members of the medical community. The outcome was overwhelmingly positive, with lots of constructive feedback and collaboration offers that we are actively considering.

We are thrilled to have received such positive feedback from the medical community, and we look forward to sharing more results as we approach the end of 2023.

We remain committed to advancing medical technology and accelerating non-invasive screening, diagnosis and monitoring of serous fluid infections, worldwide.